NeoGenomics, Inc.NEONASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank56
5Y CAGR-4.2%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-4.2%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.58% |
| Q3 2025 | -3.65% |
| Q2 2025 | -11.37% |
| Q1 2025 | 27.76% |
| Q4 2024 | 3.71% |
| Q3 2024 | -2.56% |
| Q2 2024 | 3.49% |
| Q1 2024 | 6.92% |
| Q4 2023 | 34.85% |
| Q3 2023 | -29.55% |
| Q2 2023 | 1.45% |
| Q1 2023 | 10.79% |
| Q4 2022 | -8.71% |
| Q3 2022 | -43.43% |
| Q2 2022 | 2.48% |
| Q1 2022 | 48.16% |
| Q4 2021 | 14.90% |
| Q3 2021 | 111.99% |
| Q2 2021 | 42.30% |
| Q1 2021 | 16.95% |
| Q4 2020 | 6.92% |
| Q3 2020 | -6.70% |
| Q2 2020 | 2.18% |
| Q1 2020 | -0.96% |
| Q4 2019 | -20.34% |
| Q3 2019 | 0.93% |
| Q2 2019 | 113.98% |
| Q1 2019 | 129.85% |
| Q4 2018 | 17.94% |
| Q3 2018 | -58.43% |
| Q2 2018 | 12.24% |
| Q1 2018 | 71.94% |
| Q4 2017 | -56.22% |
| Q3 2017 | 34.11% |
| Q2 2017 | 9.86% |
| Q1 2017 | -7.31% |
| Q4 2016 | -3.83% |
| Q3 2016 | -25.96% |
| Q2 2016 | -9.68% |
| Q1 2016 | -22.09% |